Published in Cancer Weekly, September 7th, 2004
The abstract, entitled "A multi-center, open-label, non-randomized Phase II study of elsamitrucin (SPI-28090) in patients with relapsed or refractory non-Hodgkin's lymphoma," presents preliminary data from patients with advanced (stage 3 or I4) NHL, all of whom had failed at least 2 (and as many as 9) prior treatment regimens. Results were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.